Eli Lilly, the drugmaker with two weight-loss bestsellers, just got its first dose of healthy skeptism during a time when the industry as a whole is fielding a lot of questions. The maker of ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

On an adjusted basis, Lilly earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

This proves that Eli Lilly's obesity drug Zepbound, as a GLP-1/GIP agonist ... will be able to take advantage of a 33.50% discount price of $399 per year. Analyst’s Disclosure: I/we have ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

Drugmaker Eli Lilly (LLY ... FDA-approved oral GLP-1 drug, Rybelsus, but its impact on weight loss has been moderate. Orforglipron, being an oral drug, will benefit Lilly in a few ways.

Could the long-running obesity drugs leadership anchored by the Denmark-headquartered Novo Nordisk (NVO) be finally coming to an end? While arch rival Eli ... actual impact. Yet, Lilly has ...